Table 6.
Study | Year | n | Treatment | Prognostic factors |
---|---|---|---|---|
Mondazzi et al.8 | 1994 | 84 | TACE | Age, total bilirubin, Child–Pugh score, tumour size, change in AFP |
Livraghi et al.16 | 1995 | 746 | PEI | Child–Pugh score, tumour stage |
Allgaier et al.17 | 1998 | 132 | TACE/PEI | Child–Pugh score, Okuda stage, PVT, AFP |
Llado et al.9 | 2000 | 143 | TACE | Ascites, AFP, tumour size, Child–Pugh score, pattern of Lipiodol intake, PVT |
El Khaddari et al.18 | 2002 | 72 | TACE | Child–Pugh score, interval between treatment |
Grieco et al.19 | 2003 | 81 | TACE | PVT, bilirubin, AFP, tumour size, Okuda, CLIP, BCLC |
Goin et al.20 | 2005 | 121 | Y-90 (Theraspheres) | Infiltrative tumour, AST/ALT > 5 ULN, tumour burden > 50%, albumin < 3.0 g/dl, bilirubin > 2 mg/dl |
Sato et al.21 | 2008 | 229 | Y-90 (Theraspheres) | Cirrhosis, infiltrative HCC, PVT, AFP, tumour burden |
TACE, transarterial chemoembolization; PEI, percutaneous ethanol injection; AFP, alphafetoprotein; PVT, portal vein thrombosis; CLIP, Cancer of the Liver Italian Programme; BCLC, Barcelona Clinic Liver Cancer; Y-90, yttrium 90 radioembolization; HCC, hepatocellular carcinoma